Mariam Swidan: IDA vs Thalassemia Trait-Disease Overview
Mariam Swidan, Biomedical Science Graduate, Clinical Laboratory Professional, shared a post on LinkedIn:
”IDA vs Thalassemia Trait-Disease Overview
Two patients.
Both have microcytic hypochromic anemia…
but completely different diagnoses.
Iron Deficiency Anemia (IDA)
One of the most common anemias worldwide.
Caused by insufficient iron, leading to lower hemoglobin synthesis – smaller, paler RBCs
Typical labs:
- Lower Hb
- Lower MCV
- High RDW
- Lower ferritin
- High TIBC
Key idea: production becomes progressively abnormal – mixed RBC sizes (high RDW) Thalassemia Trait
A genetic disorder affecting globin chain synthesis
Defective globin production – lower hemoglobin – smaller, paler RBCs
Typical labs:
- Lower MCV (often very low )
- Normal or mildly lower Hb
- RDW normal (or slightly high)
- Normal ferritin
Key idea: production is consistently abnormal- uniform RBC size (normal RDW)
Why this matters
Misdiagnosing thalassemia as IDA equals unnecessary iron therapy
Missing IDA equals untreated deficiency with real consequences
Same MCV. Different mechanism. Different management.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery